REMS PATIENT SAFETY
https://www.bmsremspatientsafety.com/
WebWelcome to the REMS Programs Administered by Bristol Myers Squibb. To avoid embryo-fetal exposure, Risk Evaluation and Mitigation Strategy (REMS) programs are mandatory for the REMS products THALOMID ® (thalidomide), POMALYST ® (pomalidomide), REVLIMID ® (lenalidomide) and generic lenalidomide.
DA: 56 PA: 70 MOZ Rank: 35